NTRA May 2024 100.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:03PM EDT. Market open.
| Previous close | 3.6000 |
| Open | 3.9000 |
| Bid | 2.1000 |
| Ask | 5.4000 |
| Strike | 100.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.8000 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 90 |
Business WireNew Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
GuruFocus.comInsider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)
On April 29, 2024, Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), sold 1,238 shares of the company.
GuruFocus.comInsider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
On April 29, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), sold 4,084 shares of the company.
© 2024 Yahoo. All rights reserved.